Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: A single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers

Clinical Therapeutics

Volumn 32, Issue 6, 2010, Pages 1178-1187

  Jung, Jinah ^a   Choi, Sangmin ^b   Cho, Sang Heon ^a   Ghim, Jong Lyul ^c   Hwang, Aekyung ^a   Kim, Unjib ^a   Kim, Bong Sik ^d   Koguchi, Atsushi ^e   Miyoshi, Shinji ^e   Okabe, Hirotaka ^e   Bae, Kyun Seop ^a   Lim, Hyeong Seok ^a  

^a University of Ulsan   (South Korea)

^b Pusan National University   (South Korea)

^c Yeungnam University   (South Korea)

^d Choongwae Pharma Co   (South Korea)

^e MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Avanafil; PDE5 inhibitor; Pharmacokinetics; Phase I; Safety

Indexed keywords

AVANAFIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; COLOR DISCRIMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MONITORING; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; ERECTILE DYSFUNCTION; EYE PAIN; FLUSHING; GLUCOSURIA; HEADACHE; HEARTBURN; HEMATURIA; HUMAN; HUMAN EXPERIMENT; KETONURIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTIPLE DRUG DOSE; NORMAL HUMAN; NOSE CONGESTION; PARESTHESIA; PENIS ERECTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOUTH KOREA; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; VITAL SIGN; VOLUNTEER;

ADULT; AREA UNDER CURVE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; MALE; PYRIMIDINES;

EID: 77954626094     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.06.011     Document Type: Article

References (27)

1. NIH Consensus Development Panel on Impotence. JAMA. 1993, 270:83-90. NIH Consensus Conference. Impotence.
2. Bivalacqua TJ, Champion HC, Hellstrom WJ, Kadowitz PJ Pharmacotherapy for erectile dysfunction. Trends Pharmacol Sci. 2000, 21:484-489.
3. Masson P, Lambert SM, Brown M, Shabsigh R PDE-5 inhibitors: Current status and future trends. Urol Clin North Am. 2005, 32:511-525.
4. Masson P, Lambert SM, Brown M, Shabsigh R PDE-5 inhibitors: Current status and future trends. Urol Clin North Am. 2005, 32:viii.
5. Francis SH, Corbin JD Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep. 2003, 4:457-465.
6. Corbin JD, Francis SH Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002, 56:453-459.
7. Palmer MJ, Bell AS, Fox DN, Brown DG Design of second generation phosphodiesterase 5 inhibitors. Curr Top Med Chem. 2007, 7:405-419.
8. Beavo JA Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev. 1995, 75:725-748.
9. Omori KM, Fujishige K Avanafil has the potential for the treatment of erectile dysfunction with selective phosphodiesterase-5. J Sex Med. 2006, 3(Suppl 3):221-222.
10. Hatzimouratidis K, Hatzichristou DG A comparative review of the options for treatment of erectile dysfunction: Which treatment for which patient?. Drugs. 2005, 65:1621-1650.
11. Peterson CS Pharmacokinetics of avanafil, a new PDE5 inhibitor being developed for erectile dysfunction. J Sex Med. 2006, 3(Suppl 3):253-254.
12. Korea good clinical practice (KGCP) guidelines Korea Food and Drug Administration, Accessed March 31, 2010. http://wwww.clinicaltrials.kfda.go.kr/guide/laws/board_list.jsp?category_seq=12.
13. Ethical principles for medical research involving human subjects. JAMA 2000, 284:3043-3045. World Medical Association Declaration of Helsinki.
14. Gonzalez CM, Bervig T, Podlasek C, et al. Sildenafil causes a dose- and time-dependent downregulation of phospho-diesterase type 6 expression in the rat retina. Int J Impot Res. 1999, 11(Suppl 1):S9-S14.
15. Arayne MS, Sultana N, Bibi Z Grape fruit juice-drug interactions. PakJ Pharm Sci. 2005, 18:45-57.
16. Bazett H An analysis of the time-relations of the electrocardiograms. Heart. 1920, 7:353-376.
17. Franklin A, Sowden P, Notman L, et al. Reduced chromatic discrimination in children with autism spectrum disorders. Dev Sci. 2010, 13:188-200.
18. Rowland M, Tozer TN Clinical Pharmacokinetics: Concepts and Applications 1995, 70:485. Williams & Wilkins, Baltimore, Md. 3rd ed.
19. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000, 17:1278-1283.
20. Mehrotra N, Gupta M, Kovar A, Meibohm B The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res. 2007, 19:253-264.
21. Dündar M, Koçak I, undar SO, Erol H Evaluation of side effects of sildenafil in group of young healthy volunteers. Int Urol Nephrol. 2001, 32:705-708.
22. Viagra (sildenafil citrate) [prescribing information]. Description, clinical pharmacology, adverse reactions. Pfizer Laboratories 2007, Accessed May 27, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020895s027lbl.pdf.
23. Padma-nathan H, Eardley I, Kloner RA, et al. A 4-year update on the safety of sildenafil citrate (Viagra). Urology. 2002, 60(Suppl 2):67-90.
24. Ochiai A, Naya Y, Soh J, et al. Efficacy of sildenafil as the first-step therapeutic tool for Japanese patients with erectile dysfunction. Int J Impot Res. 2005, 17:339-342.
25. Jeong CK, Lee HY, Jang MS, et al. Narrowbore high-performance liquid chromatography for the simultaneous determination of sildenafil and its metabolite UK-103,320 in human plasma using column switching. J Chromatogr B Biomed Sci Appl. 2001, 752:141-147.
26. Nichols DJ, Muirhead GJ, Harness JA Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: Absolute bioavail-ability, food effects and dose proportionality. Br J Clin Pharmacol. 2002, 53(Suppl 1):5S-12S.
27. Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999, 29:297-310.